Navigation Links
Catalent Experts to Present Use of Practical Aspects of New Technologies at Upcoming Bioassay Conference

Somerset, N.J. (PRWEB) March 20, 2015

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Mike Sadick, Senior Manager, Large Molecule Analytical Chemistry, and Dr. Tom Luntz, Group Leader, Cell Based Assays, will both speak at the upcoming CASSS Bioassay 2015 Conference, to be held at the Sheraton Spring Hotel, Silver Spring, MO, on March 23rd – 24th, 2015.

Dr. Sadick’s presentation, on March 23rd at 2.25 p.m., is entitled “Development and Qualification of a Robust and Easily Executable Bioassay using mRNA transcription, assessed with Dual RT-qPCR, as Assay Response,” and will demonstrate the development of a potency bioassay using transcriptional gene regulation. By using a real time quantitative reverse transcription assay, alongside a Taqman® assay chemistry in a duplex format on a cell line, Catalent has been able to develop an assay to assess induction or inhibition of ligand-induced bioactivity with excellent precision, assay range and reproducibility.

Dr. Luntz will present on March 24th, at 9.50 a.m., on the subject of “Bioassay Evolution and Lessons Learned,” and will discuss the development, evolution and validation of bioassays throughout the pathway of drug commercialization. Using practical examples, he will demonstrate how a bioassay has to be appropriate for growing demands, from initially reflecting the mechanism of action of a drug product to becoming suitable to use for future lot release and stability testing.

Dr. Sadick has over twenty five years of experience within the industry, having worked in the research faculty at UCSF Medical Centre, before joining Genentech as a Senior Scientist in the Bioassay Group supporting Pharmaceutical Science efforts (Phases I - III), and latterly as a Research Advisor at Eli Lilly and Company. He joined Aptuit in 2007 and became Senior Manager of Biopharmaceutical Characterization Services when Catalent acquired Aptuit Clinical Trials Supply in 2012.

Dr. Sadick manages the team responsible for transfer, development, validation, and performance of bioassays and the development, validation, and performance of molecular biological approaches, including qPCR and cell engineering. In addition, his group is responsible for transfer, development, validation, and performance of electro-separation techniques, including slab-gel electrophoresis and capillary electrophoresis. Dr. Sadick received his Bachelor’s Degree in Biology from Johns Hopkins University and his Master’s Degree and Ph.D. in Immunology from the University of Washington.

Dr. Luntz has 30 years of technical experience and 10 years within the industry, having worked in the Agricultural Biotechnology Research Unit (ABRU) of Ciba-GEIGY, and in the UNC School of Medicine before joining Catalent in 2005. As Group Leader of the Cell-Based Assay Group, he manages the team responsible for method development, transfer, qualification, and validation of cell-based test procedures, and also quality control testing following those methods. Dr. Luntz received his Bachelor’s Degree in Biology from Lehigh University and his Ph.D in Biochemistry from Texas A&M University.

For more information on the CASSS Bioassays Conference, visit: and to arrange a meeting with either of the Catalent executives, contact Ed Dutton at NEPR: edward(at)nepr(dot)eu

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

More products. Better treatments. Reliably supplied.™

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Catalent Announces New Organization To Speed New Products To Market
2. Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling
3. Catalent to Present Positive New Toxicology and Production Data On ADCs Generated with the SMARTag™ Technology Platform at World ADC Frankfurt Summit
4. Catalent and SELLAS Sign Exclusive Agreement for Therapeutic Reprofiling of Zolpidem
5. Catalent Applied Drug Delivery Institute Executives Invited to Speak at ‘Partnering For Cures’ Conference
6. Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition
7. Catalent Announces Two Senior Executive Appointments to Support Global Development and Clinical Services Business Growth
8. Catalent and Cingulate Therapeutics Sign Exclusive Agreement for Development of New ADHD Treatments
9. New OptiPact™ Technology Introduced by Catalent
10. Best Practice and Strategies in Risk Mitigation to be Presented by Catalent Expert at Internal Audit Summit
11. Bioavailability and Controlled Release Symposium Announced by Catalent Applied Drug Delivery Institute
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... PurhealthRX ... CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will ... and providing a CBD form that can be easily incorporated into liquid products, while ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... , ... Ellevate Network, the leading network for professional women, brought together some ... at their inaugural Summit in New York City in June. The event was livestreamed ... over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology: